Log in

NASDAQ:ALLKAllakos Stock Price, Forecast & News

$84.53
-1.97 (-2.28 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$83.72
Now: $84.53
$89.24
50-Day Range
$66.90
MA: $76.70
$86.50
52-Week Range
$41.60
Now: $84.53
$139.99
Volume310,700 shs
Average Volume345,171 shs
Market Capitalization$4.12 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.96
Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in Redwood City, California.
Read More
Allakos logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.06 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALLK
CUSIPN/A
CIKN/A
Phone650-597-5002

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$10.19 per share

Profitability

Net Income$-85,370,000.00

Miscellaneous

Employees62
Market Cap$4.12 billion
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$84.53
-1.97 (-2.28 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALLK News and Ratings via Email

Sign-up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Allakos (NASDAQ:ALLK) Frequently Asked Questions

How has Allakos' stock price been impacted by Coronavirus?

Allakos' stock was trading at $58.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALLK shares have increased by 45.0% and is now trading at $84.53.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Allakos?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Allakos
.

When is Allakos' next earnings date?

Allakos is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Allakos
.

How were Allakos' earnings last quarter?

Allakos Inc (NASDAQ:ALLK) released its earnings results on Monday, August, 10th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by $0.19.
View Allakos' earnings history
.

What price target have analysts set for ALLK?

3 analysts have issued 1 year price targets for Allakos' shares. Their forecasts range from $36.00 to $94.00. On average, they anticipate Allakos' share price to reach $65.00 in the next twelve months. This suggests that the stock has a possible downside of 23.1%.
View analysts' price targets for Allakos
.

Has Allakos been receiving favorable news coverage?

News headlines about ALLK stock have been trending extremely negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Allakos earned a media sentiment score of -4.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term.
View the latest news about Allakos
.

Who are some of Allakos' key competitors?

What other stocks do shareholders of Allakos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Alamos Gold (AGI), Eiger Biopharmaceuticals (EIGR), Eastman Chemical (EMN), Exelixis (EXEL), Gilead Sciences (GILD), General Mills (GIS) and Gold Standard Ventures (GSV).

Who are Allakos' key executives?

Allakos' management team includes the following people:
  • Dr. Robert Alexander, Pres, CEO & Director (Age 49)
  • Dr. Adam L. Tomasi, CFO, COO & Sec. (Age 49)
  • Dr. Henrik Sandvad Rasmussen, Chief Medical Officer (Age 60)
  • Dr. Ruby Casareno Ph.D., VP of Technical Operations
  • Mr. Mark Asbury, Chief Legal Officer & Gen. Counsel (Age 56)

When did Allakos IPO?

(ALLK) raised $96 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager.

What is Allakos' stock symbol?

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Who are Allakos' major shareholders?

Allakos' stock is owned by many different institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.23%), Bank of New York Mellon Corp (0.21%), Alps Advisors Inc. (0.14%), Swiss National Bank (0.11%), California Public Employees Retirement System (0.11%) and WINTON GROUP Ltd (0.08%). Company insiders that own Allakos stock include Guy P Nohra, John P Mckearn and Venture Fund (Ohi Rivervest II.
View institutional ownership trends for Allakos
.

Which major investors are selling Allakos stock?

ALLK stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc., Macquarie Group Ltd., Arizona State Retirement System, and Nisa Investment Advisors LLC. Company insiders that have sold Allakos company stock in the last year include Guy P Nohra, and John P Mckearn.
View insider buying and selling activity for Allakos
.

Which major investors are buying Allakos stock?

ALLK stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Strategic Wealth Advisors Group LLC, WINTON GROUP Ltd, SG Americas Securities LLC, Bank of New York Mellon Corp, Rafferty Asset Management LLC, ClariVest Asset Management LLC, and California Public Employees Retirement System.
View insider buying and selling activity for Allakos
.

How do I buy shares of Allakos?

Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Allakos' stock price today?

One share of ALLK stock can currently be purchased for approximately $84.53.

How big of a company is Allakos?

Allakos has a market capitalization of $4.12 billion. The company earns $-85,370,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis. Allakos employs 62 workers across the globe.

What is Allakos' official website?

The official website for Allakos is www.allakos.com.

How can I contact Allakos?

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-597-5002 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.